1. Market Research
  2. > Pharmaceutical
  3. > Biopharmaceutical Market Trends
Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024

Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024

  • March 2018
  • 255 pages
  • ID: 5365477
  • Format: PDF
  • Kuick Research

Summary

Table of Contents

“Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024” Report Highlight:
• Role of Dendritic Cells in Immune System & Cancer
• Price & Dosage Analysis of Marketed Dendritic Cell Cancer Vaccine
• Availability & Efficacy Analysis
• Marketed Dendritic Cell Cancer Vaccines Clinical Insight: 3 Vaccines
• Comparative Assessment of Provenge v/s other Key Therapeutics
• Dendritic Cell Cancer Vaccines Clinical Pipeline by Company, Indication & Phase: 63 Vaccines

Conventional therapies like surgery, radiotherapy and chemotherapies are the initial approaches for treating cancer. However, several researchers indicated that these conventional therapies are unable to treat cancer from its root cause and also produce many adverse effects thus, cannot be considered as a future of cancer therapy. Further findings demonstrated that cancer cells directly affect T-cells of the immune system and suppresses the immune activity against it resulting in uninhibited growth of cancer cells. Such incidences triggered the era of modern cancer therapy.

Advances in cellular technologies initiated the research towards exploitation of immune cells for the development of advanced vaccines for treating cancer. One of the cells which are found to be the most attractive target for developing therapeutic vaccines are Dendritic cells as they have the ability to present multiple antigens which are most suited to be a therapy for a multi-cause disease like cancer.

Dendritic cell cancer vaccines have gained significant importance in the market with the approval of first dendritic cell cancer vaccine for metastatic prostate cancer called Provenge. Provenge was approved almost a decade ago and has generated high revenues for the pharmaceutical companies. Dendritic cell vaccines became one of the most promising approaches as it works by boosting up the immune system which in turn will cause no or minimal side effects. Furthermore, cancer is disease with multiple causes and risk factors; researchers stated that instead of preventive vaccines, effective therapeutic vaccines can be developed to treat cancer.

Followed by the approval of Provenge, several similar products were developed for other indications in different regions of the world including CreaVax in South Korea for prostate and kidney cancer and Apceden in India for multiple solid tumors. Additionally, a wide range of dendritic cell vaccines entered in different phases of clinical pipeline such as Vaccell in Japan, TAP Cells in Chile, MelCancerVac in North America and Rocapuldencel-T in US etc. All these dendritic cell cancer vaccines are expected to be approved and commercialized and enhance the Global Dendritic cell vaccine market.

Dendritic cell vaccine is the fastest growing segment of cancer vaccine market with other classes of vaccine like peptide vaccines, HPV vaccine, HBV vaccines etc. Dendritic cell vaccines are more specific for treating cancer while others are limited to the treatment of chronic conditions which can cause cancer. Additionally, development of dendritic cell vaccine has been one of the fastest growing sectors amongst all and has resulted in a strong clinical pipeline with more than 60 products in different phases of clinical trials.

Moreover dendritic cell vaccines are unique of its kind which is specifically approved for advanced stages of cancer. Lack of availability of targeted therapies for advance stage of diseases, highly unmet medical needs of metastatic cancer patients indicates exponential rise in the demand for dendritic cell cancer vaccines. Furthermore, commercial successes of Provenge which is available in more than 35 countries; CreaVax in South Korea due to large target patient base has resulted in significant growth of the market.

Increasing prevalence of cancer around the globe will fuel the commercial success of unique dendritic cell vaccines. For instance, in 2018 more than 70000 and 120000 people are expected to be affected by renal cell carcinoma in US and Europe respectively which will result in great market success of Rocapuldencel-T in the coming future. Additionally, nearly 1 Million new incidences of cancer are expected to occur in Japan in 2018 which will fuel the dendritic cell cancer vaccine market in this region.

Moreover, dendritic cell vaccines are considered to be the future of cancer therapy. With the advancement in technology and better understanding of cancer cells, dendritic cells can be used as a preventive measure in the coming future. Additionally, dendritic cell cancer vaccines are one of the safest methods to treat cancer as they boost patient’s own immune system by presenting and activating specific antigens at the tumor site. Additionally, presence of a wide range of antigens in human immune system and cancer cells provides opportunities for the development of a wide range of unique products.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

CRISPR & Cas Genes Market Research Report by Component, by Application, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • October 2021
  • 190 pages

CRISPR & Cas Genes Market Research Report by Component (Product and Service), by Application (Agricultural and Biomedical), by End-user, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) ...

  • World
  • Genomics
  • Marketing Research
  • Industry analysis

ref:plp2018

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on